{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-046804","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2023-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.502242+00:00","generated_at":"2026-06-10T04:36:04.976569+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AngioDynamics Q1 FY2024 revenue $78.7M, pro-forma +5.7%; adj. loss $(0.12)/share","bullets":["Net sales $78.7M (ex-Dialysis/BioSentry +5.7% YoY); Med Tech +13.3% on Auryon +25.7%, NanoKnife +34.5%.","GAAP net income $45.9M ($1.15 EPS) includes $47.8M gain from Dialysis/BioSentry sale; adjusted loss $(0.12)/share.","Completed sale of Dialysis & BioSentry to Merit Medical for $100M cash; proceeds used to extinguish debt.","Reaffirmed FY2024 outlook: net sales $328-333M, gross margin ~50-52%, adjusted EPS loss $(0.28)-(0.34).","Cash & equivalents $57.6M at Aug 31, 2023, up from $44.6M at May 31, 2023; debt-free post-divestiture."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-046804","json":"https://secwatch.observer/filing/0001140361-23-046804.json","markdown":"https://secwatch.observer/filing/0001140361-23-046804.md","text":"https://secwatch.observer/filing/0001140361-23-046804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000114036123046804/0001140361-23-046804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000114036123046804/ef20011918_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:36:04.976569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8bf39059485d0b0f9c032ae8b858889474e02dbf","claim":"ANGIODYNAMICS INC reported the first quarter of fiscal year 2024, which ended August 31, 2023 results: revenue $78.7 million, net income $45.9 million, EPS $1.15. Guidance reaffirmed.","evidence_excerpt":"795-1408 AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance Fiscal Year 2024 First Quarter Highlights • Net sales of $78.7 million as reported o Includes $0.7 million of Dialysis and BioSentry Biopsy Tract Sealant System sales o Net sales increased 5.7% on a pro-forma basis when excluding Dialysis and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036123046804/0001140361-23-046804-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of fiscal year 2024, which ended August 31, 2023"},{"label":"Revenue","value":"$78.7 million"},{"label":"Net income","value":"$45.9 million"},{"label":"EPS","value":"$1.15"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}